Antimicrobial Agents Practice Questions

Q: In the context of HIV treatment, what is the primary purpose of combining multiple antiretroviral medications?

To prevent the development of resistance. ***To prevent the development of resistance*** - HIV has a **high mutation rate** due to its RNA genome and error-prone reverse transcriptase, allowing it to rapidly develop resistance to single antiretroviral drugs. - Combining multiple drugs that target different stages of the viral life cycle ensures that even if one drug's target mutates, other drugs can still inhibit viral replication, thereby **suppressing viral evolution** and minimizing resistance. *To reduce the pill burden* - While single-pill regimens combining multiple drugs exist, the primary goal of combining different antiretrovirals is not to reduce the number of pills, but rather to **enhance efficacy and prevent resistance**. - Reducing pill burden is a secondary benefit or an aim of drug formulation, not the fundamental purpose of combination therapy itself. *To increase the mutation rate of the virus* - This statement is incorrect; the goal of HIV treatment is to **decrease viral replication** and thus reduce the opportunity for new mutations to occur, not to increase them. - An increased mutation rate would be detrimental, leading to more rapid drug resistance and treatment failure. *To target different organs infected with HIV* - While HIV can infect various cell types and organs, the primary goal of combination antiretroviral therapy (cART) is to **reduce the viral load throughout the body** by inhibiting viral replication, regardless of the specific organ. - Different drugs target different steps of the viral life cycle, not necessarily different organ systems, but achieving systemic viral suppression benefits all affected tissues.

Q: A patient undergoing chemotherapy requires prophylactic treatment to prevent infection. Which drug is commonly prescribed for Pneumocystis pneumonia prophylaxis?

Trimethoprim-sulfamethoxazole. ***Trimethoprim-sulfamethoxazole*** - This combination antibiotic is the **most commonly prescribed and highly effective** agent for preventing **Pneumocystis pneumonia (PCP)** in immunocompromised patients, including those undergoing chemotherapy. - It works by inhibiting **folate synthesis** in *Pneumocystis jirovecii*, thereby preventing its proliferation. *Doxycycline* - **Doxycycline** is a tetracycline antibiotic primarily used for bacterial infections like pneumonia and skin infections, or for malaria prophylaxis. - It is **not effective** against *Pneumocystis jirovecii* and therefore not used for PCP prophylaxis. *Sulfadiazine* - **Sulfadiazine** is a sulfonamide antibiotic that can be used to treat toxoplasmosis, but it is **not the first-line or most effective agent** for PCP prophylaxis when used alone. - It is a component of trimethoprim-sulfamethoxazole, where the combined action is crucial for PCP prevention. *Clindamycin* - **Clindamycin** is a lincosamide antibiotic primarily used for anaerobic bacterial infections and certain protozoal infections like toxoplasmosis in combination with pyrimethamine. - It has **no significant role** in the prevention of **Pneumocystis pneumonia**.

Q: Which antiviral drug inhibits DNA polymerase, effectively preventing viral replication in herpes viruses?

Acyclovir. ***Acyclovir*** - Acyclovir is a **guanosine analog** that is selectively phosphorylated by **herpes viral thymidine kinase** within infected cells. - The activated form then inhibits **viral DNA polymerase**, leading to chain termination and preventing viral replication. *Oseltamivir* - Oseltamivir is an **antiviral medication** used to treat and prevent **influenza A and B** by inhibiting the viral enzyme **neuraminidase**. - It does not target **herpes viruses** or their **DNA polymerase**. *Ritonavir* - Ritonavir is an **antiretroviral drug** primarily used to treat **HIV infection**, often as a **pharmacokinetic booster** for other protease inhibitors. - It works by inhibiting **HIV protease**, not DNA polymerase of herpes viruses. *Zidovudine* - Zidovudine (AZT) is a **nucleoside reverse transcriptase inhibitor (NRTI)** used in the treatment of **HIV infection**. - It works by inhibiting **reverse transcriptase**, an enzyme unique to retroviruses, and is not active against herpes viral DNA polymerase.

Q: A 60-year-old man is diagnosed with hospital-acquired bacterial endocarditis and empiric broad-spectrum coverage is needed. Which beta-lactamase inhibitor combined with an anti-pseudomonal penicillin provides the broadest coverage in this context?

Tazobactam. ***Tazobactam*** - **Tazobactam** combined with **piperacillin** (piperacillin-tazobactam) provides the **broadest spectrum coverage** among beta-lactamase inhibitor combinations, particularly for hospital-acquired infections. - It is effective against a wide range of bacteria including **ESBL-producing organisms**, Pseudomonas aeruginosa, and many Gram-positive and Gram-negative bacteria. - In the context of **hospital-acquired endocarditis** where broad empiric coverage is needed, piperacillin-tazobactam is frequently chosen due to its **enhanced activity against resistant organisms** and coverage of nosocomial pathogens. *Sulbactam* - **Sulbactam** is combined with ampicillin and is effective against **beta-lactamase-producing Staphylococcus aureus** and certain Gram-negative bacteria. - While useful in some endocarditis cases (particularly community-acquired), it has a **narrower spectrum** compared to tazobactam and lacks reliable anti-pseudomonal activity. *Clavulanic acid* - **Clavulanic acid** is combined with amoxicillin or ticarcillin and covers **Gram-positive and some Gram-negative bacteria**. - Its spectrum of beta-lactamase inhibition is **more limited** than tazobactam, particularly against ESBL-producing organisms common in hospital settings. - Amoxicillin-clavulanate is rarely used for endocarditis treatment. *All of the options* - While all three are beta-lactamase inhibitors used in various infections, **tazobactam** (in combination with piperacillin) provides the **broadest spectrum** and is most appropriate for empiric therapy in hospital-acquired endocarditis requiring coverage of resistant organisms. - The choice depends on **suspected pathogen**, local resistance patterns, and infection severity, but for broad empiric coverage in nosocomial infections, piperacillin-tazobactam is preferred.

Q: A patient with tuberculosis is given a first-line treatment regimen that includes a drug that inhibits mycolic acid synthesis. Which drug is appropriate?

Isoniazid. ***Isoniazid*** - **Isoniazid** is a prodrug that, once activated by the bacterial catalase-peroxidase enzyme **KatG**, inhibits **mycolic acid synthesis**. - Its mechanism involves interfering with the synthesis of **mycolic acids**, which are essential components of the **mycobacterial cell wall**, leading to its bactericidal effect. *Rifampin* - **Rifampin** inhibits **bacterial DNA-dependent RNA polymerase (DDRP)**, thereby blocking RNA synthesis. - This drug is known for its ability to penetrate macrophages and act on bacteria within these cells, and it contributes to the sterilizing activity of TB regimens. *Pyrazinamide* - **Pyrazinamide** is a prodrug converted to pyrazinoic acid in acidic environments, which disrupts **mycobacterial metabolism** and membrane function. - Its exact mechanism is not fully understood, but it is known to be effective against **intracellular M. tuberculosis** in acidic phagosomal environments. *Ethambutol* - **Ethambutol** inhibits **arabinosyl transferase**, an enzyme involved in the synthesis of the **arabinogalactan component of the mycobacterial cell wall**. - This inhibition prevents the formation of the complex mycobacterial cell wall, making the bacteria more susceptible to other anti-TB drugs.

Q: Which drug was among the first antivirals to receive emergency authorization for COVID-19 treatment and works by inhibiting viral RNA polymerase?

Remdesivir. ***Remdesivir*** - **Remdesivir** is an **adenosine nucleotide analog** that inhibits viral **RNA-dependent RNA polymerase (RdRp)**, thereby disrupting **viral replication**. - It was **one of the first antiviral drugs** to receive emergency use authorization for treating COVID-19, particularly in **hospitalized patients with severe disease**. - Administered **intravenously**, it directly targets the viral replication machinery. *Paxlovid (nirmatrelvir-ritonavir)* - While highly effective in reducing viral replication, **Paxlovid** is a **protease inhibitor combination** with a different mechanism of action. - **Nirmatrelvir** targets the **SARS-CoV-2 main protease (Mpro)**, not RNA polymerase, preventing the virus from processing polyproteins necessary for replication. - It received authorization **later** than remdesivir and is given **orally** for outpatient use. *Molnupiravir* - **Molnupiravir** is an oral antiviral that induces **lethal mutations in viral RNA** (error catastrophe), a mechanism distinct from **RNA polymerase inhibition**. - While it reduces viral replication, it does not work by inhibiting viral RNA polymerase specifically. *Ibuprofen* - **Ibuprofen** is a **non-steroidal anti-inflammatory drug (NSAID)** used to manage **fever, pain, and inflammation** associated with COVID-19. - It has **no direct antiviral activity** and does not inhibit viral replication—it provides purely **symptomatic relief**.

Q: A patient with severe COVID-19 is treated with an adenosine nucleoside analog antiviral drug that inhibits RNA-dependent RNA polymerase. Which drug is this likely to be?

Remdesivir. ***Remdesivir*** - **Remdesivir** is an **adenosine nucleoside analog** that acts as a **prodrug** and is metabolized intracellularly to its active triphosphate form. - This active form then inhibits **viral RNA-dependent RNA polymerase (RdRp)**, thereby disrupting viral replication in severe **COVID-19**. - It has been the primary established antiviral with WHO recommendation for hospitalized patients with severe COVID-19. *Favipiravir* - **Favipiravir** is a **purine (guanine) analog** antiviral that also targets **RdRp** in RNA viruses. - While it has been explored for COVID-19 in some countries, it is chemically distinct (purine vs. adenosine analog) and lacks the same level of established efficacy evidence for severe COVID-19. - Its primary established use is for **influenza** in some regions (Japan). *Ribavirin* - **Ribavirin** is a guanosine analog with broad-spectrum antiviral activity, often used in combination therapy for **chronic hepatitis C**. - Its mechanism involves interfering with **RNA synthesis** and processing, but it is not a primary treatment for COVID-19. *Oseltamivir* - **Oseltamivir** is a **neuraminidase inhibitor** used to treat and prevent **influenza A and B**. - It works by preventing the release of new viral particles from infected cells, a mechanism distinct from **RdRp inhibition** and unrelated to COVID-19 treatment.

Q: Which macrolide drug is used as a penicillin substitute for patients who are allergic and is known to inhibit protein synthesis?

Azithromycin. ***Azithromycin*** - Azithromycin is a **macrolide antibiotic** that inhibits **bacterial protein synthesis** by binding to the **50S ribosomal subunit**. - It is frequently used as an alternative for patients with a **penicillin allergy**, especially for respiratory tract infections and some sexually transmitted infections. *Vancomycin* - Vancomycin is a **glycopeptide antibiotic** that inhibits **cell wall synthesis** by interfering with peptidoglycan formation, not protein synthesis. - It is primarily used for **MRSA infections** and *Clostridioides difficile* colitis, and is not a common penicillin substitute for general infections. *Clindamycin* - Clindamycin is a **lincosamide antibiotic** that inhibits **protein synthesis** by binding to the **50S ribosomal subunit**, similar to macrolides. - While it can be used in penicillin-allergic patients, its spectrum is more focused on **anaerobic bacteria** and some gram-positive cocci, and it is more associated with *Clostridioides difficile* infection. *Ciprofloxacin* - Ciprofloxacin is a **fluoroquinolone antibiotic** that inhibits bacterial **DNA gyrase** and **topoisomerase IV**, thereby blocking DNA replication. - It does not inhibit protein synthesis and is not typically considered a first-line penicillin substitute for common infections due to its broader spectrum and potential side effects.

Q: Which antifungal drug inhibits ergosterol synthesis and is widely used for systemic fungal infections including candidiasis and cryptococcosis?

Fluconazole. ***Fluconazole*** - Fluconazole is an **azole antifungal** that inhibits **14-alpha-demethylase**, an enzyme crucial for **ergosterol synthesis** in fungal cell membranes, thereby disrupting membrane integrity. - It is effective against a wide range of **systemic fungal infections**, particularly candidiasis, and is known for good oral bioavailability and penetration into the central nervous system. *Terbinafine* - Terbinafine is an **allylamine antifungal** that inhibits **squalene epoxidase**, an early step in ergosterol synthesis, leading to accumulation of toxic squalene. - It is primarily used for **dermatophyte infections** (e.g., onychomycosis) and less commonly for systemic fungal infections. *Amphotericin B* - Amphotericin B is a **polyene antifungal** that directly binds to **ergosterol** in the fungal cell membrane, forming pores and causing leakage of intracellular contents. - It is a **broad-spectrum antifungal** often considered a "last resort" for severe, life-threatening systemic fungal infections due to its significant toxicity. *Caspofungin* - Caspofungin is an **echinocandin antifungal** that inhibits **beta (1,3)-D-glucan synthase**, an enzyme essential for the synthesis of **glucan** in the fungal cell wall, leading to cell wall instability and lysis. - It is effective against *Candida* species and *Aspergillus* but does not target ergosterol synthesis.

Q: Which antiviral drug is most effective in treating hepatitis C due to its direct-acting antiviral mechanism?

Sofosbuvir. ***Sofosbuvir*** - **Sofosbuvir** is a **nucleotide analog inhibitor** that targets the **HCV NS5B RNA polymerase**, a crucial enzyme for viral replication. - It is a cornerstone of **direct-acting antiviral (DAA) regimens** for hepatitis C, achieving high cure rates across various genotypes [1]. *Oseltamivir* - **Oseltamivir** is an **antiviral drug** primarily used to treat and prevent **influenza A and B viruses** by inhibiting neuraminidase. - It has **no activity** against the **hepatitis C virus (HCV)**. *Lamivudine* - **Lamivudine** is a **nucleoside analog reverse transcriptase inhibitor** primarily used to treat **HIV infection** and **chronic hepatitis B virus (HBV) infection** [2]. - While it's an antiviral, it is **not effective** against the **hepatitis C virus (HCV)**. *Acyclovir* - **Acyclovir** is an **antiviral agent** specifically active against **herpes simplex viruses (HSV)** and **varicella-zoster virus (VZV)** by inhibiting viral DNA polymerase. - It has **no therapeutic role** in the treatment of **hepatitis C virus (HCV)** infection.

Question 1

In the context of HIV treatment, what is the primary purpose of combining multiple antiretroviral medications?

Accepted Answer

To prevent the development of resistance

Answer

To reduce the pill burden

Answer

To increase the mutation rate of the virus

Answer

To target different organs infected with HIV

Question 2

A patient undergoing chemotherapy requires prophylactic treatment to prevent infection. Which drug is commonly prescribed for Pneumocystis pneumonia prophylaxis?

Accepted Answer

Trimethoprim-sulfamethoxazole

Answer

Doxycycline

Answer

Sulfadiazine

Answer

Clindamycin

Question 3

Which antiviral drug inhibits DNA polymerase, effectively preventing viral replication in herpes viruses?

Accepted Answer

Acyclovir

Answer

Oseltamivir

Answer

Ritonavir

Answer

Zidovudine

Question 4

A 60-year-old man is diagnosed with hospital-acquired bacterial endocarditis and empiric broad-spectrum coverage is needed. Which beta-lactamase inhibitor combined with an anti-pseudomonal penicillin provides the broadest coverage in this context?

Accepted Answer

Tazobactam

Answer

Sulbactam

Answer

Clavulanic acid

Answer

All of the options

Question 5

A patient with tuberculosis is given a first-line treatment regimen that includes a drug that inhibits mycolic acid synthesis. Which drug is appropriate?

Accepted Answer

Isoniazid

Answer

Rifampin

Answer

Pyrazinamide

Answer

Ethambutol

Question 6

Which drug was among the first antivirals to receive emergency authorization for COVID-19 treatment and works by inhibiting viral RNA polymerase?

Accepted Answer

Remdesivir

Answer

Paxlovid (nirmatrelvir-ritonavir)

Answer

Ibuprofen

Answer

Molnupiravir

Question 7

A patient with severe COVID-19 is treated with an adenosine nucleoside analog antiviral drug that inhibits RNA-dependent RNA polymerase. Which drug is this likely to be?

Accepted Answer

Remdesivir

Answer

Favipiravir

Answer

Ribavirin

Answer

Oseltamivir

Question 8

Which macrolide drug is used as a penicillin substitute for patients who are allergic and is known to inhibit protein synthesis?

Accepted Answer

Azithromycin

Answer

Vancomycin

Answer

Ciprofloxacin

Answer

Clindamycin

Question 9

Which antifungal drug inhibits ergosterol synthesis and is widely used for systemic fungal infections including candidiasis and cryptococcosis?

Accepted Answer

Fluconazole

Answer

Terbinafine

Answer

Amphotericin B

Answer

Caspofungin

Question 10

Which antiviral drug is most effective in treating hepatitis C due to its direct-acting antiviral mechanism?

Accepted Answer

Sofosbuvir

Answer

Oseltamivir

Answer

Lamivudine

Answer

Acyclovir

Antimicrobial Agents — MCQs

Antimicrobial Agents — MCQs

On this page

Practice by Chapter

Want unlimited practice?